PE20231297A1 - Compuestos de piridotriazina sustituidos y usos de estos - Google Patents
Compuestos de piridotriazina sustituidos y usos de estosInfo
- Publication number
- PE20231297A1 PE20231297A1 PE2023002101A PE2023002101A PE20231297A1 PE 20231297 A1 PE20231297 A1 PE 20231297A1 PE 2023002101 A PE2023002101 A PE 2023002101A PE 2023002101 A PE2023002101 A PE 2023002101A PE 20231297 A1 PE20231297 A1 PE 20231297A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- halogen
- alkyloxy
- compounds
- haloalkyl
- Prior art date
Links
- HHQDNOXLJMIISM-UHFFFAOYSA-N pyrido[3,2-d]triazine Chemical class C1=NN=NC2=CC=CN=C21 HHQDNOXLJMIISM-UHFFFAOYSA-N 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 7
- 150000002367 halogens Chemical group 0.000 abstract 7
- 125000003545 alkoxy group Chemical group 0.000 abstract 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 3
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102220632799 Immunoglobulin heavy variable 1-69_R11A_mutation Human genes 0.000 abstract 1
- 102220495208 NAD(P)H pyrophosphatase NUDT13, mitochondrial_R12A_mutation Human genes 0.000 abstract 1
- 102220495705 NAD(P)H pyrophosphatase NUDT13, mitochondrial_R13A_mutation Human genes 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- AIDS & HIV (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Abstract
La presente descripcion se refiere a compuestos triciclicos de Formula I, donde Ar es arilo C6-C10 o heteroarilo de seis a diez miembros que contiene uno, dos o tres heteroatomos seleccionados de N, O, y S; en donde el arilo C6-C10 o heteroarilo de seis a diez miembros esta opcionalmente sustituido con 1-4 sustituyentes seleccionados independientemente del grupo que consiste en halogeno, alquilo C1-C6, haloalquilo C1-C6, y alquiloxi C1-C6; R1 es H, alquilo C1-C3 o fenilo; R2 es H o alquilo C1-C3; R3 es H o alquilo C1-C3; R4 y R5 son H, halogeno, ciano, alquilo C1-C6, alquiloxi C1-C6, arilo C6-C10, entre otros; R6 es H, halogeno, alquilo C1-C6, alquiloxi C1-C6 o haloalquilo C1-C6; R7 es H, halogeno, alquilo C1-C6, alquiloxi C1-C6, o haloalquilo C1-C6; R8A y R8B son H, alquilo C1-C3 o bencilo; y -X-Y- es -(CR13AR13B)p-CR9=CR10-, - o -(CR13AR13B)q-CR11AR11BCR12AR12B-; en donde R9 es H, halogeno, alquilo C1-C6, haloalquilo C1-C6 o alquiloxi C1-C6; R10 es H, halogeno, alquilo C1-C6, entre otros; R11A, R11B, R12A, R12B, R13A, y R13B son H, halogeno, alquilo C1-C6, alquiloxi C1-C6, entre otros; p es 0 o 1; q es 0 o 1. Tambien esta referida composiciones farmaceuticas que comprenden dichos compuestos y metodos para preparar dichos compuestos y composiciones farmaceuticas. Los compuestos de la descripcion son utiles para tratar o prevenir la infeccion por el virus de inmunodeficiencia humana (VIH).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163139237P | 2021-01-19 | 2021-01-19 | |
US202163190461P | 2021-05-19 | 2021-05-19 | |
PCT/US2022/012773 WO2022159387A1 (en) | 2021-01-19 | 2022-01-18 | Substituted pyridotriazine compounds and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20231297A1 true PE20231297A1 (es) | 2023-08-22 |
Family
ID=80514578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2023002101A PE20231297A1 (es) | 2021-01-19 | 2022-01-18 | Compuestos de piridotriazina sustituidos y usos de estos |
Country Status (25)
Country | Link |
---|---|
US (2) | US11613546B2 (es) |
EP (2) | EP4196479B1 (es) |
JP (1) | JP2024503116A (es) |
KR (1) | KR20230134529A (es) |
AU (1) | AU2022210247A1 (es) |
CA (1) | CA3202957A1 (es) |
CL (1) | CL2023002074A1 (es) |
CO (1) | CO2023009518A2 (es) |
CR (1) | CR20230315A (es) |
DK (1) | DK4196479T3 (es) |
DO (1) | DOP2023000139A (es) |
ES (1) | ES2968058T3 (es) |
FI (1) | FI4196479T3 (es) |
HR (1) | HRP20231654T1 (es) |
HU (1) | HUE064467T2 (es) |
IL (1) | IL304222A (es) |
LT (1) | LT4196479T (es) |
MX (1) | MX2023008137A (es) |
PE (1) | PE20231297A1 (es) |
PL (1) | PL4196479T3 (es) |
PT (1) | PT4196479T (es) |
SI (1) | SI4196479T1 (es) |
TW (1) | TWI824384B (es) |
WO (1) | WO2022159387A1 (es) |
ZA (1) | ZA202306360B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2023008137A (es) | 2021-01-19 | 2023-07-21 | Gilead Sciences Inc | Compuestos de piridotriazina sustituidos y usos de estos. |
Family Cites Families (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
SG182849A1 (en) | 2003-04-25 | 2012-08-30 | Gilead Sciences Inc | Antiviral phosphonate analogs |
EP2258376B1 (en) | 2004-07-27 | 2019-02-27 | Gilead Sciences, Inc. | Phosphonate analogs of HIV inhibitor compounds |
ATE516026T1 (de) | 2005-02-21 | 2011-07-15 | Shionogi & Co | Bicyclisches carbamoylpyridonderivat mit hiv- integrase-hemmender wirkung |
PL3045206T3 (pl) | 2005-04-28 | 2018-08-31 | Viiv Healthcare Company | Wielopierścieniowe pochodne karbamoilopirydonu wykazujące aktywność inhibitorową wobec integrazy HIV |
JP2006342115A (ja) | 2005-06-10 | 2006-12-21 | Shionogi & Co Ltd | Hivインテグラーゼ阻害活性を有する多環性化合物 |
EP1910363A4 (en) | 2005-08-04 | 2010-05-26 | Glaxosmithkline Llc | INHIBITORS OF HIV INTEGRASE |
EP1942736A2 (en) | 2005-10-27 | 2008-07-16 | Merck & Co., Inc. | Hiv integrase inhibitors |
TW200800988A (en) | 2005-10-27 | 2008-01-01 | Shionogi & Amp Co Ltd | Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity |
TW200811153A (en) | 2006-06-23 | 2008-03-01 | Japan Tobacco Inc | 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
US20100056516A1 (en) | 2006-07-17 | 2010-03-04 | Williams Peter D | 1-hydroxy naphthyridine compounds as anti-hiv agents |
WO2008048538A1 (en) | 2006-10-18 | 2008-04-24 | Merck & Co., Inc. | Hiv integrase inhibitors |
EP2220046B1 (en) | 2007-11-16 | 2014-06-18 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
EP2231621B1 (en) | 2008-01-08 | 2016-11-02 | Merck Sharp & Dohme Corp. | Process for preparing n-substituted hydroxypyrimidinone carboxamides |
US8129398B2 (en) | 2008-03-19 | 2012-03-06 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
WO2009154870A1 (en) | 2008-05-05 | 2009-12-23 | Merck & Co., Inc. | Hiv integrase inhibitors |
CA2729649A1 (en) | 2008-07-02 | 2010-01-07 | Avexa Limited | Thiazopyrimidinones and uses thereof |
KR101695807B1 (ko) | 2008-07-25 | 2017-01-13 | 비이브 헬쓰케어 컴퍼니 | 화합물 |
EP2330902B1 (en) | 2008-07-25 | 2012-11-14 | GlaxoSmithKline LLC | Chemical compounds |
EP2320908B9 (en) | 2008-07-25 | 2014-06-18 | VIIV Healthcare Company | Dolutegravir Prodrugs |
WO2010011815A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
WO2010011818A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
WO2010011819A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
WO2010042392A2 (en) | 2008-10-06 | 2010-04-15 | Merck & Co., Inc. | Hiv integrase inhibitors |
KR101687841B1 (ko) | 2008-12-09 | 2016-12-19 | 길리애드 사이언시즈, 인코포레이티드 | 톨-유사 수용체의 조절제 |
US8624023B2 (en) | 2008-12-11 | 2014-01-07 | Shionogi & Co., Ltd. | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
CA2750045A1 (en) | 2009-01-28 | 2010-08-05 | Merck Sharp & Dohme Corp. | Bridged compounds as hiv integrase inhibitors |
US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
LT2444400T (lt) | 2009-06-15 | 2018-06-11 | Shionogi & Co., Ltd. | Pakeistasis policiklinis karbamoilpiridono darinys |
WO2011011483A1 (en) | 2009-07-22 | 2011-01-27 | Glaxosmithkline Llc | Chemical compounds |
EP2470014A4 (en) | 2009-08-26 | 2013-01-16 | Merck Sharp & Dohme | HIV integrase inhibitors |
AU2010305805B2 (en) | 2009-10-13 | 2014-04-03 | Elanco Animal Health Ireland Limited | Macrocyclic integrase inhibitors |
TR201807704T4 (tr) | 2010-01-27 | 2018-06-21 | Viiv Healthcare Co | Anti-viral tedavi. |
TW201139437A (en) | 2010-02-26 | 2011-11-16 | Japan Tobacco Inc | 1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine derivative and use of the same as HIV integrase inhibitor |
JP5739517B2 (ja) | 2010-04-02 | 2015-06-24 | ヤンセン・アールアンドデイ・アイルランド | 大環状インテグラーゼ阻害剤 |
WO2011129095A1 (ja) | 2010-04-12 | 2011-10-20 | 塩野義製薬株式会社 | インテグラーゼ阻害活性を有するピリドン誘導体 |
WO2011139637A1 (en) | 2010-05-03 | 2011-11-10 | Philadelphia Health & Education Corporation | Small-molecule modulators of hiv-1 capsid stability and methods thereof |
AP2013006706A0 (en) | 2010-07-02 | 2013-02-28 | Gilead Sciences Inc | Napht-2-ylacetic acid derivatives to treat AIDS |
CN103209963A (zh) | 2010-07-02 | 2013-07-17 | 吉里德科学公司 | 作为hiv抗病毒化合物的2-喹啉基-乙酸衍生物 |
CN103154004B (zh) | 2010-08-05 | 2016-07-06 | 盐野义制药株式会社 | 具有hiv整合酶抑制活性的化合物的制造方法 |
TWI577377B (zh) | 2010-09-16 | 2017-04-11 | Viiv醫療保健公司 | 醫藥組合物 |
CA2814703A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | Hiv integrase inhibitors |
US8835411B2 (en) | 2010-12-10 | 2014-09-16 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
ES2707997T3 (es) | 2011-04-21 | 2019-04-08 | Gilead Sciences Inc | Compuestos de benzotiazol y su uso farmacéutico |
JP6205354B2 (ja) | 2011-07-06 | 2017-09-27 | ギリアード サイエンシーズ, インコーポレイテッド | Hivの処置のための化合物 |
CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
CA2851218A1 (en) | 2011-10-12 | 2013-04-18 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative having integrase-inhibiting activity |
WO2013091096A1 (en) | 2011-12-20 | 2013-06-27 | Boehringer Ingelheim International Gmbh | Condensed triclyclic compounds as inhibitors of hiv replication |
JP5911638B2 (ja) | 2012-04-20 | 2016-04-27 | ギリアード サイエンシーズ, インコーポレイテッド | ベンゾチアゾール−6−イル酢酸誘導体およびhiv感染を処置するためのそれらの使用 |
EP2865014A4 (en) | 2012-06-25 | 2015-07-29 | Sunpower Corp | REINFORCEMENT FOR NETWORK OF SOLAR MODULES |
WO2014008636A1 (en) | 2012-07-11 | 2014-01-16 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as hiv integrase inhibitors |
WO2014014933A1 (en) | 2012-07-20 | 2014-01-23 | Merck Sharp & Dohme Corp. | Hiv treatment with amido-substituted pyrimidinone derivatives |
US8906929B2 (en) | 2012-08-16 | 2014-12-09 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
DE102012220513B4 (de) | 2012-11-12 | 2023-02-16 | Bayerische Motoren Werke Aktiengesellschaft | Verfahren und Vorrichtung zur Herstellung eines Druckgussteils |
US9714243B2 (en) | 2012-12-17 | 2017-07-25 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as HIV integrase inhibitors |
MD4736C1 (ro) | 2012-12-21 | 2021-07-31 | Gilead Sciences, Inc. | Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia |
AR094311A1 (es) | 2012-12-27 | 2015-07-22 | Japan Tobacco Inc | Derivados de tetrahidroespiro-ciclopropil-pirido[1,2-a]pirazina inhibidores de la integrasa del hiv |
WO2014172188A2 (en) | 2013-04-16 | 2014-10-23 | Merck Sharp & Dohme Corp. | 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors |
SI2997033T1 (en) | 2013-05-17 | 2018-04-30 | Merck Sharp & Dohme Corp. | FUZYCLE TRICYCLE HETEROCYCLIC COMPOUNDS AS HIV INTEGRATED INHIBITORS |
EP3008044B1 (en) | 2013-06-13 | 2018-11-21 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
HUE037347T2 (hu) | 2013-07-12 | 2018-08-28 | Gilead Sciences Inc | Policiklusos karmaboilpiridon vegyületek és alkalmazásuk HIV fertõzések kezelésére |
NO2865735T3 (es) | 2013-07-12 | 2018-07-21 | ||
WO2015039348A1 (en) | 2013-09-23 | 2015-03-26 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
ES2768658T3 (es) | 2013-09-27 | 2020-06-23 | Merck Sharp & Dohme | Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del VIH |
WO2015089847A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
NO2717902T3 (es) | 2014-06-20 | 2018-06-23 | ||
US10011613B2 (en) | 2014-08-22 | 2018-07-03 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative having integrase inhibitory activity |
RU2017107715A (ru) | 2014-08-27 | 2018-09-27 | ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД | Производные имидазо[1,2-a]пиридина для применения в качестве ингибиторов репликации вируса иммунодефицита человека |
WO2016094198A1 (en) | 2014-12-09 | 2016-06-16 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
WO2016090545A1 (en) | 2014-12-09 | 2016-06-16 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrate inhibitors |
TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
EP3285582B1 (en) | 2015-03-26 | 2020-11-11 | Merck Sharp & Dohme Corp. | Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors |
PL3277691T3 (pl) | 2015-04-02 | 2019-07-31 | Gilead Sciences, Inc. | Policykliczne związki karbamoilopirydonowe i ich zastosowanie farmaceutyczne |
WO2016187788A1 (en) | 2015-05-25 | 2016-12-01 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds useful for treating hiv infection |
WO2017087257A1 (en) | 2015-11-17 | 2017-05-26 | Merck Sharp & Dohme Corp. | Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors |
WO2017087256A1 (en) | 2015-11-17 | 2017-05-26 | Merck Sharp & Dohme Corp. | Spirocyclic pyridotriazine derivatives useful as hiv integrase inhibitors |
US10544155B2 (en) | 2015-12-15 | 2020-01-28 | Merck Sharp & Dohme Corp. | Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors |
WO2017113288A1 (en) | 2015-12-31 | 2017-07-06 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
WO2017223280A2 (en) | 2016-06-23 | 2017-12-28 | Viiv Healthcare Company | Compositions and methods for the delivery of therapeutics |
RU2749043C2 (ru) | 2016-12-02 | 2021-06-03 | Мерк Шарп И Доум Корп. | Трициклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич |
JOP20190130A1 (ar) | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
WO2018109786A1 (en) | 2016-12-16 | 2018-06-21 | Cipla Limited | Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives |
WO2018140368A1 (en) | 2017-01-26 | 2018-08-02 | Merck Sharp & Dohme Corp. | Substituted quinolizine derivatives useful as hiv integrase inhibitors |
KR20200094734A (ko) | 2017-09-22 | 2020-08-07 | 주빌런트 에피파드 엘엘씨 | Pad 억제제로서의 헤테로사이클릭 화합물 |
CN111970949A (zh) | 2018-02-13 | 2020-11-20 | 冷蒸汽解决方案公司 | 用于对气流进行加湿和冷却的方法及组合物 |
EP3752144B1 (en) * | 2018-02-15 | 2022-12-28 | Merck Sharp & Dohme LLC | Tricyclic heterocycle compounds useful as hiv integrase inhibitors |
JP2021522254A (ja) | 2018-04-27 | 2021-08-30 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Hivインテグラーゼ阻害剤として有用な三環式複素環化合物 |
CN110526930B (zh) | 2018-05-23 | 2022-06-03 | 莫云芬 | 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用 |
KR20210015922A (ko) | 2018-05-31 | 2021-02-10 | 시오노기 앤드 컴파니, 리미티드 | 다환성 카바모일피리돈 유도체 |
EP3802543A1 (en) | 2018-05-31 | 2021-04-14 | F. Hoffmann-La Roche AG | Therapeutic compounds |
MX2020012185A (es) | 2018-05-31 | 2021-01-29 | Shionogi & Co | Derivado policiclico de piridona. |
WO2019236396A1 (en) | 2018-06-05 | 2019-12-12 | Merck Sharp & Dohme Corp. | Tricyclic heterocycle compounds useful as hiv integrase inhibitors |
WO2019244066A2 (en) | 2018-06-19 | 2019-12-26 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
WO2020003093A1 (en) | 2018-06-25 | 2020-01-02 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
EP3815689A4 (en) | 2018-06-27 | 2022-04-20 | National University Corporation Hokkaido University | ARENAVIRUS GROWTH INHIBITOR COMPRISING A POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE |
CA3117453A1 (en) | 2018-10-22 | 2020-04-30 | Board Of Regents Of The University Of Nebraska | Antiviral prodrugs and nanoformulations thereof |
EP3886863A4 (en) | 2018-11-29 | 2023-01-04 | Board of Regents of the University of Nebraska | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF |
WO2020197991A1 (en) | 2019-03-22 | 2020-10-01 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
WO2020221294A1 (zh) | 2019-04-30 | 2020-11-05 | 上海拓界生物医药科技有限公司 | 桥环-3,4-二氢-吡啶并[1,2-a]吡嗪-1,8-二酮化合物及其药物用途 |
RU2717101C1 (ru) | 2019-06-03 | 2020-03-18 | Андрей Александрович Иващенко | Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения |
WO2021093846A1 (zh) | 2019-11-13 | 2021-05-20 | 上海拓界生物医药科技有限公司 | 新型四环杂环化合物及其药物用途 |
WO2021107065A1 (ja) | 2019-11-28 | 2021-06-03 | 塩野義製薬株式会社 | 多環性ピリドピラジン誘導体 |
WO2021107066A1 (ja) | 2019-11-28 | 2021-06-03 | 塩野義製薬株式会社 | インテグラーゼ阻害剤及び抗hiv薬を組み合わせることを特徴とするhiv感染症の予防及び治療用医薬 |
CN115151545A (zh) | 2020-02-24 | 2022-10-04 | 吉利德科学公司 | 用于治疗hiv感染的四环化合物 |
CN116390924A (zh) | 2020-09-30 | 2023-07-04 | 吉利德科学公司 | 桥连三环氨基甲酰基吡啶酮化合物及其用途 |
MX2023008137A (es) | 2021-01-19 | 2023-07-21 | Gilead Sciences Inc | Compuestos de piridotriazina sustituidos y usos de estos. |
JP2024507788A (ja) | 2021-02-16 | 2024-02-21 | メルク・シャープ・アンド・ドーム・エルエルシー | Hivインテグラーゼ阻害剤として有用な四環式複素環化合物 |
-
2022
- 2022-01-18 MX MX2023008137A patent/MX2023008137A/es unknown
- 2022-01-18 AU AU2022210247A patent/AU2022210247A1/en active Pending
- 2022-01-18 LT LTEPPCT/US2022/012773T patent/LT4196479T/lt unknown
- 2022-01-18 TW TW111102065A patent/TWI824384B/zh active
- 2022-01-18 ES ES22704452T patent/ES2968058T3/es active Active
- 2022-01-18 SI SI202230013T patent/SI4196479T1/sl unknown
- 2022-01-18 CA CA3202957A patent/CA3202957A1/en active Pending
- 2022-01-18 PL PL22704452.6T patent/PL4196479T3/pl unknown
- 2022-01-18 KR KR1020237027739A patent/KR20230134529A/ko active Search and Examination
- 2022-01-18 HR HRP20231654TT patent/HRP20231654T1/hr unknown
- 2022-01-18 EP EP22704452.6A patent/EP4196479B1/en active Active
- 2022-01-18 WO PCT/US2022/012773 patent/WO2022159387A1/en active Application Filing
- 2022-01-18 JP JP2023543136A patent/JP2024503116A/ja active Pending
- 2022-01-18 PT PT227044526T patent/PT4196479T/pt unknown
- 2022-01-18 US US17/578,020 patent/US11613546B2/en active Active
- 2022-01-18 FI FIEP22704452.6T patent/FI4196479T3/fi active
- 2022-01-18 EP EP23205202.7A patent/EP4321217A3/en active Pending
- 2022-01-18 PE PE2023002101A patent/PE20231297A1/es unknown
- 2022-01-18 CR CR20230315A patent/CR20230315A/es unknown
- 2022-01-18 DK DK22704452.6T patent/DK4196479T3/da active
- 2022-01-18 HU HUE22704452A patent/HUE064467T2/hu unknown
-
2023
- 2023-02-03 US US18/164,317 patent/US11897892B2/en active Active
- 2023-06-19 ZA ZA2023/06360A patent/ZA202306360B/en unknown
- 2023-07-03 IL IL304222A patent/IL304222A/en unknown
- 2023-07-17 CO CONC2023/0009518A patent/CO2023009518A2/es unknown
- 2023-07-17 DO DO2023000139A patent/DOP2023000139A/es unknown
- 2023-07-17 CL CL2023002074A patent/CL2023002074A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2024503116A (ja) | 2024-01-24 |
EP4196479B1 (en) | 2023-11-01 |
ES2968058T3 (es) | 2024-05-07 |
CA3202957A1 (en) | 2022-07-28 |
PL4196479T3 (pl) | 2024-03-18 |
HUE064467T2 (hu) | 2024-03-28 |
FI4196479T3 (fi) | 2024-01-17 |
HRP20231654T1 (hr) | 2024-03-15 |
IL304222A (en) | 2023-09-01 |
EP4196479A1 (en) | 2023-06-21 |
WO2022159387A1 (en) | 2022-07-28 |
CL2023002074A1 (es) | 2024-01-12 |
PT4196479T (pt) | 2024-01-03 |
TWI824384B (zh) | 2023-12-01 |
CR20230315A (es) | 2023-09-01 |
KR20230134529A (ko) | 2023-09-21 |
MX2023008137A (es) | 2023-07-21 |
LT4196479T (lt) | 2023-12-11 |
DOP2023000139A (es) | 2023-08-15 |
AU2022210247A1 (en) | 2023-08-17 |
EP4321217A3 (en) | 2024-04-10 |
DK4196479T3 (da) | 2024-01-22 |
US11613546B2 (en) | 2023-03-28 |
US11897892B2 (en) | 2024-02-13 |
TW202237128A (zh) | 2022-10-01 |
SI4196479T1 (sl) | 2024-01-31 |
AU2022210247A9 (en) | 2024-05-09 |
CO2023009518A2 (es) | 2023-07-21 |
US20220267343A1 (en) | 2022-08-25 |
US20230257389A1 (en) | 2023-08-17 |
ZA202306360B (en) | 2024-04-24 |
EP4321217A2 (en) | 2024-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20231377A1 (es) | Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica | |
PE20220905A1 (es) | Pirroles triciclicos condensados como moduladores de alfa-1 antitripsina | |
PE20211655A1 (es) | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 | |
PE20000048A1 (es) | Prodrogas de inhibidores de aspartil proteasa | |
PE20230376A1 (es) | Compuestos moduladores de la diacilglicerol quinasa | |
AR053014A1 (es) | Compuestos de pirazol inhibidores de raf quinasa | |
AR064414A1 (es) | Derivados de 1-azoniabiciclo[2, 2, 2]octano y 1-azabiciclo[2, 2, 2]oct-3-ilo, un proceso para su preparacion, una composicion farmaceutica que los comprende, procedimiento de obtencion de la misma, su uso en la elaboracion de un medicamento para el tratamiento de epoc y un producto farmaceutico que | |
PE20220808A1 (es) | Derivados de benzisoxazol sulfonamida | |
AR030324A1 (es) | Derivados de 4-fenil-piridina | |
AR064304A1 (es) | Formulaciones de ansamicina y sus metodos de uso | |
AR042192A1 (es) | Derivados antivirales de nucleosidos de pirimidina | |
AR056838A1 (es) | Derivados de 1,2,5-tiadiazol | |
UY25682A1 (es) | Procedimiento para preparar derivados de quinolin-2-ona alquinilsustituidos útiles como agentes anticancerosos entre otras acciones terapéuticas | |
AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
RU2010116253A (ru) | Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила | |
AR043367A2 (es) | Derivados de benzofenona, composiciones farmaceuticas y procesos de preparacion. | |
PE20231297A1 (es) | Compuestos de piridotriazina sustituidos y usos de estos | |
PE20201414A1 (es) | Derivado policiclico de piridona | |
SE0300120D0 (sv) | Novel compounds | |
PE20240775A1 (es) | Compuestos antivirales | |
AR116400A1 (es) | Compuesto de imidazopiridinona | |
PE20221006A1 (es) | Compuestos antibacterianos para el tratamiento de la enfermedad de la bacteriana por "enterobacteriaceae" | |
PE20230182A1 (es) | Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter | |
AR034585A1 (es) | Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos |